Tarceva Ushering OSI Toward Critical Juncture' In Evolution Sep. 27, 2004 By Randy Osborne Tarceva, the eye-opening cancer drug with a new drug application pending, typically is regarded as another feather in the cap of Genentech Inc., whose headgear already is festooned with plumage.Read More
Manufacturing, Marketing And Distribution Agreements Between Biotech Companies: June 24 - Sept. 16, 2004 Sep. 20, 2004
Biotech - Biotech Collaborations: Modified And Terminated Agreements, June 24 - Sept. 16, 2004 Sep. 20, 2004
RSS